Reconstitution comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
According to the Centers for Disease Control and Prevention (CDC), average U.S. life expectancy at birth reached 79.0 years in 2024, its highest recorded level and an increase of 0.6 years over 2023. The CDC attributed the improvement mainly to lower mortality from unintentional injuries, COVID-19, heart disease, cancer, and homicide. Heart disease, cancer, and unintentional injuries remained the leading causes of death. In 2024, life expectancy at birth for American men rose to 76.5 years (+0.7 years compared to 2023), while life expectancy for women was 81.4 years (+0.3 years). Starting in 1998, life expectancy in the U.S. fell behind that of other wealthy industrialized countries, and Americans' "health disadvantage" gap has been increasing ever since. The Commonwealth Fund reported in 2020 that the U.S. had the highest suicide rate among the 11 high-income countries included in its study. Obesity affected 40.3% of U.S. adults aged 20 and older in August 2021–August 2023. The U.S. healthcare system far outspends that of any other country, measured both in per capita spending and as a percentage of GDP, but attains worse healthcare outcomes when compared to peer countries for reasons that are debated. The United States is the only developed country without a system of universal healthcare, and a significant proportion of the population that does not carry health insurance. Government-funded healthcare coverage for the poor (Medicaid) and for those age 65 and older (Medicare) is available to Americans who meet the programs' income or age qualifications.
Immuno-ligation methods High-throughput multiplex assays allow for the simultaneous detection of multiple proteins and thus improve profiling capabilities. This is opening up avenues to even more clinical applications with increased precision and biology.
The panel noted the large number of failures to replicate excess heat and the greater inconsistency of reports of nuclear reaction byproducts expected by established conjecture. Nuclear fusion of the type postulated would be inconsistent with current understanding and, if verified, would require established conjecture, perhaps even theory itself, to be extended in an unexpected way. The panel was against special funding for cold fusion research, but supported modest funding of "focused experiments within the general funding system". Cold fusion supporters continued to argue that the evidence for excess heat was strong, and in September 1990 the National Cold Fusion Institute listed 92 groups of researchers from 10 countries that had reported corroborating evidence of excess heat, but they refused to provide any evidence of their own arguing that it could endanger their patents. However, no further DOE nor NSF funding resulted from the panel's recommendation. By this point, academic consensus had moved decidedly toward labeling cold fusion as a kind of "pathological science". In March 1990, Michael H. Salamon, a physicist from the University of Utah, and nine co-authors reported negative results. University faculty were then "stunned" when a lawyer representing Pons and Fleischmann demanded the Salamon paper be retracted under threat of a lawsuit. The lawyer later apologized; Fleischmann defended the threat as a legitimate reaction to alleged bias displayed by cold-fusion critics.
The first three prize winners at the late coursing meeting at Great Bend were trained on Spratt's Patent Dog Biscuit. This same dog food won no less than three awards, including a gold medal, at the Exposition in Paris which has just closed. It would seem that the decision of the judges is more than backed up by the result in the kennel. Another good dog food is that manufactured by Austin & Graves, of Boston. They, too, seem to be meeting with great success in their line. Canned horse meat was introduced in the United States under the Ken-L Ration brand after World War I as a means to dispose of excess horses no longer needed for the war. The 1930s saw the introduction of canned cat food and dry meat-meal dog food by the Gaines Food Co. By the time World War II ended, pet food sales had reached $200 million. In the 1950s Spratt's became part of General Mills. For companies such as Nabisco, Quaker Oats, and General Foods, pet food represented an opportunity to market by-products as a profitable source of income.
Sources: en.wikipedia.org
=== United States === The seaweed has been found in several harbors in southern California. In May 2009 it was discovered in San Francisco Bay and aggressive efforts are underway to remove it before it spreads.
Vanilla planifolia has been propagated clonally through cuttings rather than from seeds and selective breeding. As of 2023 there is only one patented cultivar, "Handa", and very few other named cultivars. The most important of these cultivars for commercial growing are the "Mansa" types. There are also two variegated cultivars sold for ornamental gardening. Though there are five known attempted introductions to Reunion Island between 1793 and 1875, only the 1822 introduction was successful. It is likely that almost all the vanilla grown in the areas surrounding the Indian Ocean are descended from this one introduction and this is supported by modern genetic research. Vanilla as a crop could be threatened by this genetic bottleneck and the subsequent buildup of negative mutations. Because of the low rate of natural pollination, even in areas with pollinators, which are rare to nonexistent elsewhere, the flowers must be hand-pollinated when grown on farms. Once beans in a cluster turn yellow and ripe, the whole cluster is generally harvested and cured. Curing involves fermentation and drying of the pod to develop the characteristic vanilla flavor while minimizing the loss of essential oils. Vanilla extract is obtained from this portion of the plant. It is cultivated and harvested primarily in Veracruz, Mexico, Tahiti, Indonesia, and Madagascar. V. planifolia can be grown and harvested indoors as a houseplant or in a greenhouse, but it has very precise requirements for growing conditions. It is generally only attempted by experts in orchid cultivation.
== Awards and honours == Robinson has received many honors working as a cellular biologist. She was awarded a Wellcome Trust Principal Research Fellowship in 1999 and in 2003 she was appointed Professor of Molecular Cell Biology. She was elected a Fellow of the Academy of Medical Sciences in 2001 and member of the European Molecular Biology Organization in the same year. She was elected a Fellow of the Royal Society (FRS) in 2012. The Wellcome Trust also has funded her research for over 25 years.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.